Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) – Pipeline Review, H2 2017’, provides in depth analysis on Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Cardiovascular, Central Nervous System and Musculoskeletal Disorders under development targeting Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)

The report reviews Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics and enlists all their major and minor projects

The report assesses Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Boehringer Ingelheim GmbH

Genervon Biopharmaceuticals LLC

MedImmune LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Overview 6

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 12

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Companies Involved in Therapeutics Development 20

Boehringer Ingelheim GmbH 20

Genervon Biopharmaceuticals LLC 20

MedImmune LLC 21

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Drug Profiles 22

dusigitumab - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

GM-6 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

M-610.27 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

M-630 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

M-7085 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Recombinant Proteins to Inhibit IGF-2 for Oncology - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecules to Inhibit IGF-2 for Oncology - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

xentuzumab - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Dormant Products 36

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Product Development Milestones 37

Featured News & Press Releases 37

Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published 37

Jan 10, 2017: Genervon Releases ALS, PD and AD Disease­ Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm 37

Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways 38

Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS 39

May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604 39

May 03, 2016: GM604 to Be Granted “Orphan Drug” Status in Europe 40

Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression 41

Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease 41

Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA 42

Jan 08, 2015: Genervon Announces ALS Compassionate Use Results 43

Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results 44

Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS 46

Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS 46

Mar 03, 2014: FDA Grants “Orphan Drug” Designation for Genervon’s Breakthrough Multi-Target ALS Bio-Drug GM604 47

Jun 26, 2013: Genervon's GM604 Receives Fast Track Designation From FDA For Treatment Of Amyotrophic Lateral Sclerosis 47

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products under Investigation by Universities/Institutes, H2 2017 12

Products under Investigation by Universities/Institutes, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Pipeline by Boehringer Ingelheim GmbH, H2 2017 20

Pipeline by Genervon Biopharmaceuticals LLC, H2 2017 20

Pipeline by MedImmune LLC, H2 2017 21

Dormant Projects, H2 2017 36

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports